ANAB:NASDAQ, AnaptysBio, Inc.
ANAB stock overview
AnaptysBio, Inc. (ANAB:NASDAQ) closed at $45.73 on November 16, 2026,
down 1.12% on the day.
The stock trades 36.8% below its 52-week high of $72.36
and 107.8% above its 52-week low of $22.01.
Over the past year, it gained 97.3%.
AnaptysBio, Inc. is part of the Health Care sector (Major Pharmaceuticals).
Key figures
- Price
- $45.73
- Day change
- -1.12%
- Volume
- 483,756
- Average volume
- 479,632
- Market cap
- 1B+
- 52-week range
- $22.01 – $72.36
- 50-day average
- $49.79
- 200-day average
- $51.20
Price action over the past year
In 252 trading sessions since November 14, 2025, ANAB closed higher on 129 days (51%).
Its best day was April 24, 2026 (+14.84%) and its worst was July 20, 2026 (-13.29%).
The stock moved 10% or more in a single session 8 times.
Recent signals
ANAB news
-
Nov 12, 2026:
AnaptysBio, Inc. (ANAB) Misses Q3 Earnings and Revenue Estimates
-
Nov 12, 2026:
Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
-
Nov 12, 2026:
EyePoint (EYPT) Reports Q3 Loss, Beats Revenue Estimates
-
Nov 10, 2026:
Anaptys Announces Participation in Upcoming Investor Conferences
-
Oct 31, 2026:
AnaptysBio (ANAB) vs. PTCT and MIRM: Is the Market Missing the Value of Its Royalty Stream and Legal Upside?
-
Oct 30, 2026:
Is AnaptysBio (ANAB) Undervalued Following Jemperli's Early FDA Approval?
-
Oct 28, 2026:
Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth
-
Oct 27, 2026:
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
About AnaptysBio, Inc.
AnaptysBio Inc is a biotechnology company. The Company is engaged in developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. Its product include ANB020 and ANB019.
Similar stocks
Find more stocks like ANAB with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.